John Finn, Ph.D.
Basecamp Analysis
Finn, an trade chief within the area of cell and gene remedy, will lead firm’s efforts to advance groundbreaking approaches to programmable genetic medicines
Workplace and lab in Kendall Sq. (Cambridge, Mass.) to deal with increasing Firm’s community of best-in-class therapeutic partnerships
New, purpose-built NVIDIA accelerated computing cluster – one of the vital superior industrial compute infrastructures in Europe – matches the corporate’s distinctive information benefit and fuels the design of fully new organic methods
LONDON and CAMBRIDGE, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) — Basecamp Research, an AI firm devoted to fixing probably the most urgent challenges in life sciences, at the moment introduced that John Finn, Ph.D., will be part of as Chief Scientific Officer (CSO) as the corporate establishes a Boston lab and workplace to speed up its pursuit of programmable genetic medicines.
“John is a globally-recognised chief in cell and gene remedy who has spent greater than 25 years pursuing extraordinarily advanced scientific and technological challenges,” stated Glen Gowers, Ph.D., Basecamp Analysis co-founder and CEO. “With John’s expertise, our enormous information benefit and our pioneering new class of basis fashions, Basecamp Analysis is positioned to transcend identified biology and obtain groundbreaking advances that enhance human well being.”
Finn most not too long ago served as Chief Scientific Officer of Tome Biosciences, the place he pioneered new strategies of enormous gene insertion for therapeutic functions. He additionally held senior management positions at Codiak BioSciences and Intellia Therapeutics. He has devoted his profession to advancing the sector of gene and cell remedy by means of improvements in each supply and modifying applied sciences. He obtained his Ph.D. in Biochemistry and Molecular Biology from The College of British Columbia and did post-doctoral analysis at McMaster College and the Youngsters’s Hospital of Philadelphia.
“I used to be drawn to Basecamp Analysis due to the unbelievable alternative to develop the following era of programmable genetic medicines and handle challenges going through the sector at the moment,” Finn stated. “Basecamp Analysis’s benefit of an unlimited and distinctive dataset, mixed with its subsequent era of AI fashions, actually enhances my expertise in genetic medicines. I am excited to see how we will leverage these synergies to proceed my life’s mission of advancing scientific discoveries that may result in new remedies for sufferers in want.”
Expanded Workforce and Footprint in Boston’s Kendall Sq.
Finn will be part of a rising crew, together with the corporate’s Chief Industrial Officer Anupama Hoey, on the firm’s new lab and workplace in Kendall Sq., a world-renowned biotechnology innovation district in Cambridge, Mass. These amenities add to the corporate’s skill to validate refined organic methods designed by its basis fashions.
Additionally becoming a member of the Cambridge workplace alongside Finn is Konstantinos Andrikopoulos as Senior Vice President for Mental Property. Andrikopoulos brings 27 years of pharma IP expertise, together with senior positions at Biogen, Tome Biosciences and Vertex Prescription drugs.
Pairing Information with Compute to Allow Scaling of AI Basis Fashions
To design these programmable medicines, Basecamp Analysis is constructing new lessons of foundational AI fashions which can be able to tackling more and more advanced organic design challenges.
The Firm’s current $60 million Collection B spherical has already fueled a speedy growth of their proprietary foundational dataset, permitting it to gather 10 occasions extra information within the final three months than was collected within the earlier three years.
Alongside this growth of information comes a corresponding growth of compute energy. Basecamp Analysis has constructed one of the vital superior industrial compute infrastructures in Europe. The cluster, comprising NVIDIA H200 GPUs, is without doubt one of the first to be purpose-built for coaching long-context AI basis fashions. Basecamp Analysis wants this lengthy context functionality to work with the ever-increasing high-quality genomic information it’s amassing around the globe.
Basecamp Analysis has constructed one of many world’s largest industrial biodiscovery program, spanning greater than 120 areas in over 25 nations, to provide its AI fashions an entire understanding of the true breadth and complexity of biology.
The Firm makes use of this mixture of proprietary information and highly effective fashions in a variety of partnerships, together with a multi-year collaboration with the laboratory of Dr. David R. Liu at the Broad Institute of MIT and Harvard and partnerships with three of the highest 10 pharmaceutical corporations.
About Basecamp Analysis
Basecamp Analysis is fixing probably the most urgent challenges within the life sciences by exploring past identified biology. We construct foundational AI fashions on prime of the world’s largest, ethically-sourced database of organic data to provide AI probably the most full understanding of biology ever. This enables us to design extra advanced organic methods than anybody else with efficiency enhancing dramatically as AI sees extra variety and context. Basecamp Analysis collaborates with biopharma corporations and tutorial analysis establishments to design novel protein sequences and organic methods that may rework therapeutic analysis and growth. Our crew of explorers, scientists and coverage consultants proudly work with greater than 100 biodiversity companions throughout the globe, permitting us to ship breakthroughs that may have a profound affect on healthcare and the lives of sufferers. Basecamp Analysis was named considered one of Bloomberg’s “Prime 25 UK Startups to Watch” for 2024.
For extra data, go to basecamp-research.com.
Media Contact:
Adam Silverstein
SCIENT PR
Images accompanying this announcement can be found at
https://www.globenewswire.com/NewsRoom/AttachmentNg/08653abb-fe4a-4b97-a0a5-0d23cb388440
https://www.globenewswire.com/NewsRoom/AttachmentNg/2be838aa-4ea2-49bc-8ab3-9698c86a6c0b
